ADCs (Antibody-Drug Conjugates)
Designed for highly potent compounds, the platform supports ADC development from early-stage research through GMP manufacturing and commercial scale-up.
Biosol is developing integrated antibody-drug conjugate capabilities that combine biologics expertise with specialized conjugation, containment and manufacturing infrastructure. Designed to support highly potent compounds and complex development programs, the platform enables partners to advance ADC candidates from early development through GMP manufacturing and future commercial scale-up.
Capabilities Include:
- Bioconjugation
- Purification
- Analytical Development
- Formulation Development
- Fill-Finish
- Lyophilization
- GMP Manufacturing
Manufacturing Scale
- 2g - 20g Development Scale
- 20L - 200L GMP Manufacturing Scale
- OEB-5 Containment Infrastructure